NasdaqGS - Nasdaq Real Time Price USD

Apellis Pharmaceuticals, Inc. (APLS)

49.86

+1.93

(+4.03%)

At close: April 26 at 4:00 PM EDT

51.25

+1.39

(+2.79%)

After hours: April 26 at 7:59 PM EDT

Apellis Announces Pegcetacoplan MAA Review Has Been Reset to Day 180 of Initial Assessment by European Medicines Agency (EMA)

Decision by EMA follows recent judgment by the Court of Justice of the European Union regarding the organization of EMA’s expert groupsApellis anticipates a CHMP opinion no later than July 2024 WALTHAM, Mass., April 26, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the European Medicines Agency (EMA) has reset the review of the marketing authorization application (MAA) for intravitreal pegcetacoplan for geographic atrophy to the last phase of the init

GlobeNewswire 2 days ago
Apellis Pharmaceuticals to Host Conference Call on May 7, 2024, to Discuss First Quarter 2024 Financial Results

WALTHAM, Mass., April 23, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a conference call and webcast to discuss its first quarter 2024 financial results on Tuesday, May 7, 2024, at 8:30 a.m. ET. To access the live call by phone, please pre-register for the call here. A live audio webcast of the event and accompanying slides may also be accessed through the “Events and Presentations” page of the “Investors and Media” section of t

GlobeNewswire 5 days ago
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass., April 04, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company approved the grant of equity awards to one new employee with a grant date of April 1, 2024, as equity inducement awards outside of the company's 2017 Stock Incentive Plan (but under the terms of the 2020 Inducement Stock Incentive Plan) and material to the employees’ acceptance of employment with the company. The equity awards were approved in accordance with Nasdaq Li

GlobeNewswire 23 days ago
Apellis Pharmaceuticals to Host a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference

WALTHAM, Mass., April 01, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Monday, April 8, 2024, at 12:45 p.m. ET. The live conference webcast will be posted on the “Events and Presentations” page of the “Investors and Media” section of the company’s website. A replay of the webcast will be available for approximately 90 days following the event. About Apel

GlobeNewswire 27 days ago
Apellis Appoints Leading Expert Dr. Philip Ferrone as Chief Medical Retina Advisor

WALTHAM, Mass., March 11, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that leading retina specialist Philip Ferrone, M.D., will join the company as Chief Medical Retina Advisor, effective March 18. “Phil is globally renowned for his leadership in retina, including as a past president of the American Society of Retina Specialists (ASRS), so we are delighted to welcome him to the Apellis team,” said Caroline Baumal, M.D., Chief Medical Officer, Apellis. “P

GlobeNewswire last month
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results

Generated $397 million in full year 2023 revenues, including $275 million for SYFOVRE® (pegcetacoplan injection) and $91 million for EMPAVELI® (pegcetacoplan)Strong SYFOVRE launch, with more than 160,000 total doses (commercial and samples) distributed in 2023 Topline data from Phase 3 VALIANT study of systemic pegcetacoplan in C3G and IC-MPGN expected in mid-2024Cash and cash equivalents of $351 million as of December 31, 2023 WALTHAM, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceut

GlobeNewswire last month
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

WALTHAM, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq: APLS) today announced that the company will participate in the following March investor conferences: TD Cowen 44th Annual Healthcare Conference: Fireside chat on Monday, March 4, 2024, at 2:10 p.m. ETOphthalmology Corporate Panel Discussion on Tuesday, March 5, 2024, at 9:10 a.m. ET Raymond James & Associates’ 45th Annual Institutional Investors Conference: Fireside chat on Tuesday, March 5, 2024, at 11:00

GlobeNewswire 2 months ago
Apellis Pharmaceuticals to Host Conference Call on February 27, 2024, to Discuss Fourth Quarter and Full Year 2023 Financial Results

WALTHAM, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a conference call and webcast to discuss its fourth quarter and full year 2023 financial results on Tuesday, February 27, 2024, at 8:30 a.m. ET. To access the live call by phone, please pre-register for the call here. A live audio webcast of the event and accompanying slides may also be accessed through the “Events and Presentations” page of the “Investors and

GlobeNewswire 2 months ago
Apellis Announces Negative CHMP Opinion for Pegcetacoplan for GA in the European Union and Plans to Seek Re-Examination of Application

WALTHAM, Mass., Jan. 26, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a negative opinion on the marketing authorization application (MAA) of intravitreal pegcetacoplan for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). As previously announced, this opinion was expected based on a negative trend vote fol

GlobeNewswire 3 months ago
Apellis Announces Preliminary Fourth Quarter and Full Year 2023 U.S. Net Product Revenues

Approximately $114 million in preliminary fourth quarter SYFOVRE® revenue as strong launch continuesApproximately $24 million in preliminary fourth quarter EMPAVELI® revenue WALTHAM, Mass., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced preliminary U.S. net product revenues of approximately $138 million for the fourth quarter and approximately $366 million for the full year 2023 for SYFOVRE® (pegcetacoplan injection) for geographic atrophy (GA) sec

GlobeNewswire 3 months ago
Apellis Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

WALTHAM, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024, at 9:45 a.m. PT. The event will be available via a live webcast from the “Events and Presentations” page of the “Investors and Media” section of the company’s website. A replay of the webcast will be available for approximately 30 days following the event. About ApellisApellis

GlobeNewswire 3 months ago
Apellis Pharmaceuticals to Host a Fireside Chat at the Goldman Sachs Healthcare C-Suite Unscripted Conference

WALTHAM, Mass., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a fireside chat at the Goldman Sachs Healthcare C-Suite Unscripted Conference on Thursday, January 4, 2023, at 2:25 p.m. ET. The event will be available via a live webcast from the “Events and Presentations” page of the “Investors and Media” section of the company’s website. A replay of the webcast will be available for approximately 90 days following the even

GlobeNewswire 3 months ago
Apellis Provides Update on Ongoing Regulatory Review of Pegcetacoplan for GA in the European Union

Conference call today at 8:30 a.m. ETWALTHAM, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) announced today an update on the ongoing review of its marketing authorization application (MAA) for intravitreal pegcetacoplan for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD) by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). Following the oral explanation meeting on

GlobeNewswire 4 months ago
EMPAVELI® (pegcetacoplan) Provided Long-Term Control of PNH in New Data Presented at ASH Annual Meeting

Rapid improvements in key markers of disease were sustained for up to three years across all adults with PNHMajority of patients remained transfusion free over the long termZero cases of meningococcal infection observed over three years in this analysisData shared during an oral presentation WALTHAM, Mass., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi today presented post hoc data that reinforce the long-term efficacy and safety of EMPAVELI® (pegcetacop

GlobeNewswire 4 months ago
Apellis Pharmaceuticals to Host a Fireside Chat at the 6th Annual Evercore ISI HealthCONx Conference

WALTHAM, Mass., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), today announced that the company will host a fireside chat at the 6th Annual Evercore ISI HealthCONx Conference on Tuesday, November 28, 2023, at 10:00 a.m. ET. The event will be available via a live webcast from the “Events and Presentations” page of the “Investors and Media” section of the company’s website. A replay of the webcast will be available for approximately 90 days following the event. Abo

GlobeNewswire 5 months ago
SYFOVRE® (pegcetacoplan injection) Continued to Demonstrate Increasing Treatment Effects Over 3 Years in Patients with Geographic Atrophy (GA)

SYFOVRE reduced nonsubfoveal GA lesion growth by over 40% (monthly) in Year 3 compared to projected sham in the GALE extension studyWell-demonstrated safety profile consistent with previously reported clinical dataApproximately 92% of patients enrolled in GALE completed the first year of the study, demonstrating robust long-term complianceData were presented during an oral presentation at the American Academy of Ophthalmology (AAO) Annual Meeting A Media Snippet accompanying this announcement is

GlobeNewswire 5 months ago
Apellis Pharmaceuticals Reports Third Quarter 2023 Financial Results

Generated total revenues of $110.4 million in the third quarter, including $75.3 million for SYFOVRE® (pegcetacoplan injection) and $23.9 million for EMPAVELI® (pegcetacoplan) SYFOVRE showed continued strong demand with growth week-over-week starting in August; permanent J-code effective as of October 1Completed corporate restructuring aimed at driving growth of SYFOVRE and EMPAVELI and strengthening operational efficienciesPositive top-line data from Phase 2 NOBLE study investigating pegcetacop

GlobeNewswire 5 months ago
Apellis Pharmaceuticals to Host Conference Call on November 1, 2023, to Discuss Third Quarter 2023 Financial Results

WALTHAM, Mass., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a conference call and webcast to discuss its third quarter 2023 financial results on Wednesday, November 1, 2023, at 8:00 a.m. ET. To access the live call by phone, please pre-register for the call here. A live audio webcast of the event and accompanying slides may also be accessed through the “Events and Presentations” page of the “Investors and Media” sectio

GlobeNewswire 6 months ago
The Lancet Publishes 24-Month Results from Phase 3 Studies of SYFOVRE® (pegcetacoplan injection) for Geographic Atrophy (GA)

SYFOVRE demonstrated clinically meaningful reductions in GA lesion growth in as few as six doses per yearOnly treatment approved for use beyond 12 months for GA, a chronic disease and leading cause of vision loss WALTHAM, Mass., Oct. 20, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that The Lancet published the positive 24-month results from the Phase 3 OAKS and DERBY studies evaluating SYFOVRE® (pegcetacoplan injection) for geographic atrophy (GA) second

GlobeNewswire 6 months ago
Apellis to Present Positive Phase 2 NOBLE Results of Pegcetacoplan in Post-Transplant Recurrence of Primary IC-MPGN and C3G at Kidney Week

In as early as 12 weeks: 80% of patients treated with pegcetacoplan showed a reduction in C3c staining by one or more orders of magnitude of intensity from baseline40% of patients showed zero staining intensity, indicating that C3c deposits were cleared Pegcetacoplan-treated patients showed improvements across key clinical measures, including proteinuria, and stable kidney functionNo approved treatment for IC-MPGN and C3G, rare diseases that often lead to kidney failure WALTHAM, Mass., Oct. 17,

GlobeNewswire 6 months ago

Performance Overview

Return	APLS	S&P 500
YTD	-16.71%	+6.92%
1-Year	-42.97%	+25.26%
3-Year	+12.78%	+22.00%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Apellis Pharmaceuticals, Inc. (APLS)

Apellis Announces Pegcetacoplan MAA Review Has Been Reset to Day 180 of Initial Assessment by European Medicines Agency (EMA)

Apellis Pharmaceuticals to Host Conference Call on May 7, 2024, to Discuss First Quarter 2024 Financial Results

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apellis Pharmaceuticals to Host a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference

Apellis Appoints Leading Expert Dr. Philip Ferrone as Chief Medical Retina Advisor

Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results

Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

Apellis Pharmaceuticals to Host Conference Call on February 27, 2024, to Discuss Fourth Quarter and Full Year 2023 Financial Results

Apellis Announces Negative CHMP Opinion for Pegcetacoplan for GA in the European Union and Plans to Seek Re-Examination of Application

Apellis Announces Preliminary Fourth Quarter and Full Year 2023 U.S. Net Product Revenues

Apellis Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Apellis Pharmaceuticals to Host a Fireside Chat at the Goldman Sachs Healthcare C-Suite Unscripted Conference

Apellis Provides Update on Ongoing Regulatory Review of Pegcetacoplan for GA in the European Union

EMPAVELI® (pegcetacoplan) Provided Long-Term Control of PNH in New Data Presented at ASH Annual Meeting

Apellis Pharmaceuticals to Host a Fireside Chat at the 6th Annual Evercore ISI HealthCONx Conference

SYFOVRE® (pegcetacoplan injection) Continued to Demonstrate Increasing Treatment Effects Over 3 Years in Patients with Geographic Atrophy (GA)

Apellis Pharmaceuticals Reports Third Quarter 2023 Financial Results

Apellis Pharmaceuticals to Host Conference Call on November 1, 2023, to Discuss Third Quarter 2023 Financial Results

The Lancet Publishes 24-Month Results from Phase 3 Studies of SYFOVRE® (pegcetacoplan injection) for Geographic Atrophy (GA)

Apellis to Present Positive Phase 2 NOBLE Results of Pegcetacoplan in Post-Transplant Recurrence of Primary IC-MPGN and C3G at Kidney Week

Performance Overview